@article{Kzyrgalin, Sh.R.2026-05-27,
author = { Kzyrgalin, Sh.R.,  Yamidanov, R.S.,  Rizvanov, A.A.,  Gantsev, Sh.Kh.},
title = {Cytotoxic Activity of the New Molecular Complex DHMEQ and Ammonium Glycyrrhizinate},
year = {2025},
doi = {10.30683/1929-2279.2025.14.16},
publisher = {NP «NEICON»},
abstract = {Abstract: Objective: This study aimed to investigate the cytotoxic activity of a new molecular complex consisting of
DHMEQ and ammonium glycyrrhizinate, as well as its effect on the transcription factor NF-κB. Cytotoxicity was assessed
using the PrestoBlue® viability assay in HEK293, A-549, and MCF-7 cell lines. NF-κB inhibition was evaluated via a
luciferase reporter assay in HEK293 cells. The complex was prepared at a 1:4 molar ratio (DHMEQ:ammonium
glycyrrhizinate), and its structure was confirmed using spectroscopic methods and electron microscopy. Statistical
analysis was performed using one-way ANOVA followed by Dunnett’s post hoc test.
Results: DHMEQ demonstrated high cytotoxic activity (IC50 = 13.82 ± 3.71 µM in HEK293 cells). The
DHMEQ/ammonium glycyrrhizinate complex maintained comparable activity (IC50 = 10.39 ± 1.84 µM for HEK293) but
showed reduced efficacy against A-549 and MCF-7 tumor cells. DHMEQ strongly inhibited NF-κB activity (IC50 = 0.83 ±
0.51 µM), while the complex required significantly higher concentrations (IC50 = 21.79 ± 6.24 µM) to achieve a similar
inhibitory effect.
Conclusion: The DHMEQ–ammonium glycyrrhizinate complex preserved the main biological properties of DHMEQ while
improving its solubility and stability. This approach shows potential for developing DHMEQ-based drug formulations
targeting NF-κB, but further optimization and in vivo validation are required before clinical application.},
URL = {https://repo.bashgmu.ru/publication/5425},
eprint = {https://repo.bashgmu.ru/files/5619},
journal = {JOURNAL OF CANCER RESEARCH UPDATES},
}